Advertisement

Vasculitis

  • Jason Liebowitz
  • Brendan Antiochos
  • Eric J. GapudEmail author
Chapter

Abstract

Systemic vasculitides are a collection of inflammatory diseases that share the pathogenic feature of inflammation focused in the wall of blood vessels. The clinical manifestations of vasculitis can be greatly varied according to which caliber of blood vessel is involved. Recognizing the features of vasculitis and identifying the type of vasculitis as primary or secondary is an essential skill for rheumatologists. In this chapter, we provide a conceptual framework for the understanding of the pathophysiology, diagnosis, and treatment of the major forms of vasculitis, as well as clinical pearls that will be helpful to the practicing clinician.

Keywords

Vasculitis Fibrinoid necrosis Leukocytoclasis Mononeuritis multiplex Angiography 

References

  1. 1.
    Suresh E. Diagnostic approach to patients with suspected vasculitis. Postgrad Med J. 2006;82(970):483–8.CrossRefGoogle Scholar
  2. 2.
    Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ, Malayeri AA, Merkel PA, Novakovich E, Bluemke DA, Ahlman MA. 18 F-Fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol. 2018;70(3):439–49.CrossRefGoogle Scholar
  3. 3.
    Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317–28.CrossRefGoogle Scholar
  4. 4.
    Serra R, Butrico L, Fugetto F, Chibireva MD, Malva A, De Caridi G, Massara M, Barbetta A, Cannistrà M, de Franciscis S. Updates in pathophysiology, diagnosis and management of Takayasu’s arteritis. Ann Vasc Surg. 2016;35:210–25.CrossRefGoogle Scholar
  5. 5.
    Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129–34.CrossRefGoogle Scholar
  6. 6.
    Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007;56(3):1000–9.CrossRefGoogle Scholar
  7. 7.
    Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, European Vasculitis Study Group. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318–23.CrossRefGoogle Scholar
  8. 8.
    Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS. Takayasu arteritis. Ann Intern Med. 1994;120(11):919–29.CrossRefGoogle Scholar
  9. 9.
    Lunardi C, Bason C, Leandri M, Navone R, Lestani M, Millo E, Benatti U, Cilli M, Beri R, Corrocher R, Puccetti A. Autoantibodies to inner ear and endothelial antigens in Cogan’s syndrome. Lancet. 2002;360(9337):915–21.CrossRefGoogle Scholar
  10. 10.
    International Study Group for Behcet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335(8697):1078–80.Google Scholar
  11. 11.
    Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012;51(5):887–900.CrossRefGoogle Scholar
  12. 12.
    Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS. Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol. 2008;27(2):201–5.CrossRefGoogle Scholar
  13. 13.
    Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, Cohen P, French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore). 2005;84(5):313–22.CrossRefGoogle Scholar
  14. 14.
    Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, Bienvenu B, Mouthon L, Guillevin L, French Vasculitis Study Group. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616–26.CrossRefGoogle Scholar
  15. 15.
    Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P, French Vasculitis Study Group (FVSG). The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19–27.CrossRefGoogle Scholar
  16. 16.
    Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315(6):341–7.CrossRefGoogle Scholar
  17. 17.
    Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488–98.CrossRefGoogle Scholar
  18. 18.
    Langford C. Clinical features and diagnosis of small-vessel vasculitis. Cleve Clin J Med. 2012;79(Suppl 3):S3–7.CrossRefGoogle Scholar
  19. 19.
    Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310–7.CrossRefGoogle Scholar
  20. 20.
    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32.CrossRefGoogle Scholar
  21. 21.
    Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, Amouroux J, Casassus P, Jarrousse B. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42(3):421–30.CrossRefGoogle Scholar
  22. 22.
    Millet A, Pederzoli-Ribeil M, Guillevin L, Witko-Sarsat V, Mouthon L. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? Ann Rheum Dis. 2013;72(8):1273–9.CrossRefGoogle Scholar
  23. 23.
    Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115(4):284–90.CrossRefGoogle Scholar
  24. 24.
    Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci. 2005;1051:121–31.CrossRefGoogle Scholar
  25. 25.
    Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, Luqmani R, Brown J, Mallett S, Philipson R, Yancey SW, Steinfeld J, Weller PF, Gleich GJ, EGPA Mepolizumab Study Team. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921–32.CrossRefGoogle Scholar
  26. 26.
    Mahr A, Battistella M, Bouaziz JD, Chaigne-Delalande S. L47. Single-organ vasculitis: conceptual and practical considerations. Presse Med. 2013;42(4 Pt 2):628–34.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Jason Liebowitz
    • 1
  • Brendan Antiochos
    • 1
  • Eric J. Gapud
    • 1
    Email author
  1. 1.Johns Hopkins Vasculitis Center, Division of RheumatologyBaltimoreUSA

Personalised recommendations